Repligen (RGEN) 2026 KeyBanc Capital Markets Healthcare Forum summary

Strategic positioning and innovation

• Maintains a broad, differentiated product portfolio with 80% of offerings considered unique, focusing on innovation to improve customer yield and manufacturing costs.

• Product lines like ATF and pre-packed columns are highlighted for process intensification and operational expertise, with ongoing development of next-generation technologies.

• Differentiation in the remaining 20% of the portfolio is achieved through superior customer service and responsiveness, especially in fluid management.

• Increasingly packages technologies into full workflow solutions, enhancing value for large pharma and CDMO clients.

• Collaboration with industry peers, such as Sartorius, continues on select technologies, while competitive overlap remains limited.

Commercial momentum and customer engagement

• Visibility and engagement with large pharma and CDMO clients have grown significantly, with the number of product lines sold to major accounts increasing 2.5 times over five years.

• Now participates in 80-90% of major RFPs for new bioprocessing plants, covering nearly 80% of required equipment.

• Talent acquisition has been strong, enabling recruitment of top industry professionals across all functions.

• Expertise in column packing and bioprocessing is seen as a key competitive advantage, with over 3,000 columns packed annually.

Financial performance and guidance

• Achieved strong margin expansion in 2025, with EBIT margin up 240 basis points (excluding M&A), and targets 30% EBITDA and 25%+ EBIT by 2030.

• Margin growth expected to accelerate post-2028 as investments in growth infrastructure taper off.

• 2026 guidance remains consistent with prior years, aiming for at least 5% growth above market, despite headwinds in gene therapy.

• CapEx spending in hardware was flat in 2025, outperforming competitors, but broader industry CapEx recovery is anticipated to be a future tailwind.